Mirum Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Allowance for Credit Loss
Mirum Pharmaceuticals, Inc. (MIRM) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2024-11-12
- 2024-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2023-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-15 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |